Search Results
Dr. Kuruvilla on the Safety of Pembrolizumab in Classical Hodgkin Lymphoma
Dr. Kuruvilla on the Broad Utility of Pembrolizumab in Hodgkin Lymphoma
John Kuruvilla: Pembrolizumab in Relapsed/Refractory Classic Hodgkin Lymphoma
Outcomes of patients with Hodgkin lymphoma undergoing alloHSCT after pembrolizumab therapy
Dr. Kuruvilla on the Treatment Landscape in Relapsed/Refractory Hodgkin Lymphoma
KEYNOTE-204 in R/R classical Hodgkin lymphoma
Pembrolizumab Improves PFS in Hodgkin Lymphoma Compared With Brentuximab Vedotin
Concurrent pembrolizumab and chemotherapy in classical Hodgkin lymphoma
Lymphoma Treatment Options John Kuruvilla
Phase III KEYNOTE-204: does prior therapy impact outcomes in R/R cHL?
Checkpoint inhibitors in Hodgkin lymphoma
John Kuruvilla, ASCO20: Results of the KEYNOTE-204 Phase III Trial in Patients with cHL
